Table 5.
Correlation of CD28 expression with clinicopathological features in PCa patients.
| Clinical features | TMA | TCGA | ||||||
|---|---|---|---|---|---|---|---|---|
| Case | Low, n (%) | High, n (%) | P | Case | Low, n (%) | High, n (%) | P | |
| Tissue | ||||||||
| Cancer | 70 | 35 (50.00) | 35 (50.00) | 0.554 | 427 | 213 (49.88) | 214 (50.12) | – |
| Non-cancer | 10 | 4 (40.00) | 6 (60.00) | – | 0 | – | – | – |
| Age (years) | ||||||||
| ≤60 | 14 | 9 (64.29) | 5 (35.71) | 0.200 | 190 | 98 (51.58) | 92 (48.42) | 0.530 |
| >60 | 66 | 30 (45.45) | 36 (54.55) | – | 237 | 115 (48.52) | 122 (51.48) | – |
| Gleason score | ||||||||
| ≤8 | 46 | 25 (54.35) | 21 (45.65) | 0.314 | 300 | 156 (52.00) | 144 (48.00) | 0.179 |
| >8 | 24 | 10 (41.67) | 14 (58.33) | – | 127 | 57 (44.88) | 70 (55.12) | – |
| Serum PSA levels (ng/ml) | ||||||||
| ≤2 | – | – | – | – | 378 | 193 (51.06) | 185 (48.94) | 0.026 * |
| >2 | – | – | – | – | 35 | 11 (31.43) | 24 (68.57) | – |
| Pathological grade | ||||||||
| pT1-pT2 | 4 | 1 (25.00) | 3 (75.00) | 0.317 | – | – | – | – |
| pT3 | 65 | 33 (50.77) | 32 (49.23) | – | – | – | – | – |
| Tumor stage | ||||||||
| T1 | 0 | – | – | – | 153 | 88 (57.52) | 65 (42.48) | 0.138 |
| T2 | 42 | 23 (54.76) | 19 (45.24) | 0.272 | 155 | 76 (49.03) | 79 (50.97) | – |
| T3 | 14 | 10 (71.43) | 4 (28.57) | – | 48 | 20 (41.67) | 28 (58.33) | – |
| T4 | 0 | – | – | – | 1 | 0 (0.00) | 1 (100.00) | – |
| Lymph nodemetastasis | ||||||||
| N0 | 56 | 33 (58.93) | 23 (41.07) | – | 303 | 148 (48.84) | 155 (51.16) | 0.215 |
| N1 | 0 | – | – | – | 69 | 28 (40.58) | 41 (59.42) | – |
| Distant metastasis | ||||||||
| M0 | 56 | 33 (58.93) | 23 (41.07) | – | 401 | 199 (49.63) | 202 (50.37) | 0.574 |
| M1 | 0 | – | – | – | 3 | 1 (33.33) | 2 (66.67) | – |
＊means the difference is significant at the 0.05 level.